BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The stock market is waiting on a follow through day. Miami's eMerge Americas conference may provide some surprise energy for ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...

Summit Therapeutics Inc., a biopharmaceutical company ... and societal friendly medicinal therapies in the United States, and the United Kingdom. Its lead development candidate, ivonescimab ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday announced an agreement with the University of California ...